CUMULUS NEUROSCIENCE LIMITED

Cumulus Neuroscience Limited is a pioneering Irish‑based biotech firm that has created NeuLogiq®, the world’s most advanced, at‑home, medical‑grade platform for collecting and analysing functional brain‑health data. Built in partnership with leading global pharmaceutical companies, NeuLogiq combines a 510(k)‑cleared, flexible EEG headset with tablet‑based cognitive assessments, facial‑expression analysis, speech‑language diagnostics and remote sleep monitoring. The platform delivers frequent, reliable longitudinal data from both clinic and home settings, enabling precise tracking of neuronal integrity, network connectivity and behavioural performance across memory, executive function, decision‑making and emotional processing.

Through its proprietary AI‑driven analytics, Cumulus transforms this rich, multi‑modal dataset into actionable insights that accelerate CNS drug development, improve patient stratification and support earlier diagnosis of brain disorders such as Alzheimer’s, aphasia and other dementias. The company’s unique Pharma Advisory Group, a paid‑in consortium of top pharmaceutical partners, underpins its clinical‑trial expertise and ensures that NeuLogiq is already being employed in several ongoing studies. With a dedicated team of 30 engineers, scientists and business professionals, Cumulus Neuroscience is reshaping how brain health is measured, monitored and ultimately treated.